Pirtobrutinib is a reversible Bruton's tyrosine kinase (BTK) inhibitor that has shown efficacy for patients with chronic lymphocytic leukemia (CLL) in BRUIN trial. Here, BTK is linked to B-cell chronic lymphocytic leukemia.